Items Tagged ‘abiraterone’

June 7th, 2017

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival

By

Adding Zytiga (abiraterone acetate) plus prednisone to standard hormonal therapy for men with newly diagnosed, metastatic prostate cancer lowers the chance of death by 38%, and more than doubled the median time until the cancer worsened, from 14.8 months to 33 months according to the results of a clinical study featured at the 2017 American […]

View full entry

Tags: abiraterone, hormone refractory, metastatic prostate cancer, News, Prostate Cancer, zytiga